Cargando…
Exploring the role of immune checkpoint inhibitors in the etiology of myasthenia gravis and Lambert-Eaton myasthenic syndrome: A systematic review
BACKGROUND: While immune checkpoint inhibitors (ICIs) have been revolutionary in the treatment of cancer, their administration has been associated with a variety of immune-related adverse events (irAEs), including myasthenia gravis (MG), and Lambert-Eaton myasthenic syndrome (LEMS). OBJECTIVE: To pr...
Autores principales: | Seligman, Carly, Chang, Yu-Mei, Luo, Jie, Garden, Oliver A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9868566/ https://www.ncbi.nlm.nih.gov/pubmed/36698907 http://dx.doi.org/10.3389/fneur.2022.1004810 |
Ejemplares similares
-
A Patient with Coexisting Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome
por: Kim, Jee-Ae, et al.
Publicado: (2012) -
Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome: New Developments in Diagnosis and Treatment
por: Pascuzzi, Robert M, et al.
Publicado: (2022) -
Recent Advances and Therapeutic Options in Lambert-Eaton Myasthenic Syndrome
por: Anwar, Arsalan, et al.
Publicado: (2019) -
Amifampridine for Lambert-Eaton myasthenic syndrome
Publicado: (2022) -
Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic
por: Jacob, Saiju, et al.
Publicado: (2020)